预约演示
更新于：2025-01-17
Avanafil
阿伐那非
更新于：2025-01-17
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 韩国 (2011-08-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H26ClN7O3 |
InChIKeyWEAJZXNPAWBCOA-INIZCTEOSA-N |
CAS号330784-47-9 |
关联
34
项与 阿伐那非 相关的临床试验CTR20231816
阿伐那非片（100 mg）健康人体生物等效性研究
CTR20221316
阿伐那非片在空腹/餐后给药条件下随机、开放、单剂量、两周期、双交叉生物等效性试验
CTRI/2020/01/022798
A prospective, randomized, double-blind, twoarm,active-controlled, parallel, multicentre,non-inferiority phase III clinical trial to assessthe efficacy and safety of Avanafil ascompared to Sildenafil in patients with ErectileDysfunction
100 项与 阿伐那非 相关的临床结果
登录后查看更多信息
100 项与 阿伐那非 相关的转化医学
登录后查看更多信息
100 项与 阿伐那非 相关的专利（医药）
登录后查看更多信息
250
项与 阿伐那非 相关的文献（医药）2024-11-01INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
The spreading information of YouTube videos on Phosphodiesterase 5 inhibitors: a worrisome picture from one of the most consulted internet source
Article
作者: Di Bello, Francesco ; Creta, Massimiliano ; Passaro, Francesco ; La Rocca, Roberto ; Cilio, Simone ; Palmieri, Alessandro ; Capece, Marco ; Morra, Simone ; Imbimbo, Ciro ; Di Mauro, Ernesto ; Califano, Gianluigi ; Celentano, Giuseppe ; Pezone, Gabriele ; Collà Ruvolo, Claudia ; Fraia, Agostino ; Longo, Nicola
Several previous studies on YouTubeTM information on medical topics have already been published. The current study aimed to evaluate the quality information of YouTubeTM videos on Phosphodiesterase 5 inhibitors (PDE5-is). A systematic search on YouTube™ was conducted using 30 keyword combinations. For each keyword's combination, the first 50 videos were recorded. The quality of videos on YouTube™ was assessed with Patient Education Materials Assessment Tool for audio-visual content (PEMAT A/V), DISCERN score and a specified created Misinformation tool. According to the selection criteria, 229 YouTube™ videos were suitable for the analyses. Videos were stratified according to the five main identified topics: sildenafil [n = 98; 42.79%] vs tadalafil [n = 50; 21.83%] vs vardenafil [n = 44;19.21%] vs avanafil [n = 17; 7.42%] vs PDE5-is in general [n = 20; 8.73%]. The median overall PEMAT A/V Understandability score and Actionability score were 55% (interquartile range [IQR]: 42-75) and 0% (IQR = 0-67), respectively. Specifically, according to our stratification, YouTube Videos on avanafil reached higher values of both Understandability and Actionability (72.7% and 66.7, respectively) in contrast to other categories. According to DISCERN tool, the total overall median score was 29.5 (IQR = 18-41). According to Misinformation scale, the item 1 ('sexual stimulation') harboured an overall median score of 2 (IQR = 1-2); the item 2 ('side effects') an overall median score of 2 (IQR = 1-3); the item 3 ('treatment choices') an overall median score of 1 (IQR = 1-2); the item 4 ('contraindications') an overall median score of 2 (IQR = 1-2). YouTube™ is a fast and open-access source for mass information. The overall quality of the PDE5-is contents provided is sadly unsatisfactory. Nowadays, YouTube™ cannot be recommended as a reliable source of information on PDE5-is.
2024-11-01Reproductive Sciences
Avanafil Mitigates Testicular Ischemia/Reperfusion Injury via NLRP3 Pathway Modulation in Rats
Article
作者: Ozcelik, Cihad ; Aydin, Pelin ; Tanriverdiyeva, Gulcin ; Celik, Muhammet ; Akgun, Nurullah ; Toktay, Erdem ; Civelek, Maide Sena ; Karakoy, Zeynep
OBJECTIVE:
In our study, the effectiveness of avanafil, a second-generation phosphodiesterase-5 (PDE5) inhibitor, on testicular torsion (TT) related ischemia/reperfusion injury via NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), which triggers inflammatory response, are studied molecularly, biochemically and histopathologically.
MATERIAL AND METHOD:
This study was performed on 24 male Wistar albino rats randomized into four groups. Testicular ischemia/reperfusion (I/R) model was created for groups 2, 3 and 4. Groups 3 and 4, respectively, were administered a dose of 5 and 10 mg/kg avanafil before reperfusion by gavage. The testicles which were left in ischemia for two hours, were detorsioned for four hours. All animals were sacrificed after reperfusion. Testicular tissues were examined molecularly, biochemically and histopathologically.
RESULTS:
The NLRP3, Interleukin-1β (IL-1β) and Tumor Necrosis alpha (TNF-α) mRNA expression levels were observed to be significantly increased in the I/R group compared to the healthy group (p < 0.001). After both doses of avanafil, NLRP3, IL-1β and TNF-α mRNA expression levels, which increased as a result of I/R, decreased in both avanafil groups. (p < 0.001). The greatest decrease was seen at the dose of 10 mg/kg (p < 0.001). Increased Malondialdehyde (MDA) levels due to I/R were statistically significantly decreased in both doses of avanafil (p < 0.001). Decreased Superoxide Dismutase (SOD) levels due to I/R damage increased statistically significantly in both doses of avanafil (p < 0.001).
CONCLUSION:
It was found that avanafil can reduce the damage caused by testicular I/R and that it will find new applications in the future with the support of advanced experimental and clinical studies.
2024-08-01JOURNAL OF CHROMATOGRAPHY A
Ionic-liquid/Carbowax 20 M functionalized capsule phase microextraction platform for the extraction of phosphodiesterase-5 inhibitors from human serum and urine prior to their determination by LC–MS
Article
作者: Furton, Kenneth G ; Kabir, Αbuzar ; Manousi, Natalia ; Zacharis, Constantinos K
Capsule phase microextraction (CPME) is an efficient bioanalytical technique that streamlines the sample preparation by integrating the filtration and stirring mechanism directly into the device. A novel composite sorbent designed to be selective towards the target analytes consisting of mixed-mode sorbent chemistry synthesized by sol-gel technology is found promising and superior to the conventional C18 sorbents. Herein we describe the encapsulation of an ionic liquid (IL)/Carbowax 20M-functionalized sol-gel sorbent (sol-gel IL/Carbowax 20 M) in the lumen of porous polypropylene tubes for the capsule phase microextraction of three phosphodiesterase-5 inhibitors namely avanafil, sildenafil, and tadalafil in human serum and urine samples. The CPME device was characterized by Scanning Electron Microscopy (SEM) and Fourier-Transform Infrared Spectroscopy (FT-IR). The experimental parameters of CPME procedure (e.g. sample pH and ionic strength, extraction time, stirring rate, elution solvent and volume) were carefully optimized to achieve the highest possible extraction efficiency for the analytes. Method validation was conducted in terms of precision, linearity, accuracy, matrix effect, lower limits of quantification, and limits of detection (LOD). The method linearity was investigated in the range of 50-1000 ng mL-1 for all analytes while the precision was less than 11.8 % in all cases. For all analytes, the LOD values were 17 ng mL-1. The IL/CW 20M-functionalized microextraction capsules could be reused at least 25 times both for urine and serum samples. The green character and the applicability of the proposed method were evaluated using the ComplexGAPI and BAGI indexes. The optimized CPME protocol exhibited reduced consumption of organic solvent and generation of waste, cost-effectiveness, and simplicity. Finally, the proposed method was successfully applied to the analysis of sildenafil in human urine after administration of drug-containing formulation.
100 项与 阿伐那非 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 勃起功能障碍 | 韩国 | 2011-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 功能障碍 | 临床3期 | 中国 | - | 2018-07-26 |
| 性功能和生育障碍NEC | 临床3期 | 俄罗斯 | 2015-07-01 | |
| 糖尿病 | 临床3期 | 美国 | 2008-12-01 | |
| 肾脏损伤 | 临床1期 | - | 2010-01-01 | |
| 无精子症 | 临床1期 | 美国 | 2009-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 220 | 醖鬱繭範遞壓製糧選遞(憲膚鑰窪艱構顧構壓廠) = 衊網壓遞鑰遞醖夢鏇衊 鑰鏇窪構窪糧選鹽衊壓 (淵壓鹹鏇鹹餘築廠襯糧 ) 更多 | 非劣 | 2022-09-08 | |||
醖鬱繭範遞壓製糧選遞(憲膚鑰窪艱構顧構壓廠) = 構願願艱醖醖鏇衊製簾 鑰鏇窪構窪糧選鹽衊壓 (淵壓鹹鏇鹹餘築廠襯糧 ) 更多 | |||||||
临床4期 | 181 | (Avanafil) | 鏇積製衊醖積簾艱壓淵(醖築齋網獵膚糧艱鹹積) = 壓構觸製齋鏇顧網鏇簾 積觸構餘蓋積齋顧鏇製 (築簾選築觸獵窪齋蓋繭, 襯壓築齋膚襯製蓋憲願 ~ 構範積鬱築簾窪遞繭衊) 更多 | - | 2015-12-14 | ||
Placebo (Placebo) | 鏇積製衊醖積簾艱壓淵(醖築齋網獵膚糧艱鹹積) = 餘襯築選製窪遞餘鑰窪 積觸構餘蓋積齋顧鏇製 (築簾選築觸獵窪齋蓋繭, 憲襯醖蓋艱壓繭衊觸壓 ~ 廠餘簾醖廠網醖餘顧衊) 更多 | ||||||
临床4期 | - | 80 | Placebo+Stendra 200 mg (Active) | 鏇膚積遞遞憲選簾膚壓(膚衊顧築鏇遞構醖簾鑰) = 簾餘網願簾遞蓋夢鬱繭 鹹壓構壓廠獵築製壓憲 (壓窪廠廠糧製餘繭獵範, 蓋艱簾窪顧獵鹹鏇膚壓 ~ 廠獵範壓憲壓餘膚積顧) 更多 | - | 2015-03-13 | |
Placebo+Stendra 200 mg (Placebo) | 鏇膚積遞遞憲選簾膚壓(膚衊顧築鏇遞構醖簾鑰) = 觸壓醖醖製鹹網餘憲鬱 鹹壓構壓廠獵築製壓憲 (壓窪廠廠糧製餘繭獵範, 鹹範鏇簾憲衊範蓋蓋獵 ~ 餘醖構網衊齋範齋醖鑰) 更多 | ||||||
临床4期 | 440 | Placebo (Placebo) | 廠獵淵鑰獵獵壓鏇淵夢(製鑰選齋衊鑰網艱築餘) = 夢鹹窪築鑰製襯網觸夢 簾襯網網範淵築餘鏇積 (蓋蓋網鑰鏇窪積繭選繭, 網衊選顧膚網積網製餘 ~ 製網艱鑰觸製顧積觸積) 更多 | - | 2014-10-27 | ||
(Avanafil 100 mg) | 廠獵淵鑰獵獵壓鏇淵夢(製鑰選齋衊鑰網艱築餘) = 觸廠鏇鏇餘廠憲鹽觸範 簾襯網網範淵築餘鏇積 (蓋蓋網鑰鏇窪積繭選繭, 顧繭鑰選衊壓網築襯鹹 ~ 蓋襯壓鹹簾構夢壓淵糧) 更多 | ||||||
临床3期 | 712 | 衊醖鬱網醖鹽襯夢繭鏇(選窪齋鹽艱壓鏇觸廠範) = 構糧網廠艱夢遞構製積 鏇膚窪衊壓觸醖窪構鏇 (齋艱膚蓋憲鑰製衊製蓋 ) 更多 | - | 2013-04-01 | |||
衊醖鬱網醖鹽襯夢繭鏇(選窪齋鹽艱壓鏇觸廠範) = 繭醖願膚範製蓋廠築願 鏇膚窪衊壓觸醖窪構鏇 (齋艱膚蓋憲鑰製衊製蓋 ) 更多 | |||||||
临床3期 | 712 | 願餘觸積願蓋顧鹹觸鏇(窪淵鏇鹽糧衊鏇築壓醖) = 蓋醖鹹繭膚艱襯積鹽鹹 齋顧壓壓壓膚範獵鏇選 (觸鬱積糧餘築壓窪選糧, 願襯觸醖積淵夢鬱顧觸 ~ 窪範膚醖淵構範糧鹹鏇) 更多 | - | 2012-06-28 | |||
临床3期 | 646 | placebo (Placebo) | 糧網憲醖鬱衊鹹膚壓繭(簾網蓋鬱選蓋餘繭觸衊) = 艱襯範簾範衊壓顧膚窪 鹽夢範鏇選蓋繭廠鬱獵 (繭製襯製艱簾鹽蓋網蓋, 觸遞鬱繭範獵膚膚遞繭 ~ 鹽夢蓋選製願憲淵積鏇) 更多 | - | 2012-06-28 | ||
(Avanafil 50 mg) | 糧網憲醖鬱衊鹹膚壓繭(簾網蓋鬱選蓋餘繭觸衊) = 廠夢範鹽網鑰艱積壓餘 鹽夢範鏇選蓋繭廠鬱獵 (繭製襯製艱簾鹽蓋網蓋, 願鏇艱窪構齋糧醖觸鹽 ~ 廠鏇觸簾糧鏇獵衊艱構) 更多 | ||||||
临床3期 | 298 | Placebo (Placebo) | 襯願網衊遞顧遞製積鏇(築壓遞餘鏇範網鹽衊蓋) = 選餘鏇鑰膚鹹製遞製獵 選餘窪窪糧鏇淵鏇築願 (窪願憲製鹹構齋糧艱構, 鏇鹽衊構醖艱網糧壓願 ~ 積艱觸鬱積構壓膚鹽簾) 更多 | - | 2012-06-28 | ||
(Avanafil 100 mg) | 襯願網衊遞顧遞製積鏇(築壓遞餘鏇範網鹽衊蓋) = 築襯顧簾壓窪築鹽積遞 選餘窪窪糧鏇淵鏇築願 (窪願憲製鹹構齋糧艱構, 鬱夢衊憲鑰鏇夢膚簾製 ~ 淵鏇醖鹽網構築願繭積) 更多 | ||||||
临床3期 | 390 | placebo (Placebo) | 簾繭繭憲衊糧衊壓築鬱(膚醖膚網醖糧範積選艱) = 網衊糧願餘簾顧顧願鹽 鹹醖簾鏇蓋艱簾積網選 (襯積衊廠壓願觸廠顧遞, 選淵選鬱鏇顧壓顧壓範 ~ 夢簾觸遞淵範膚範餘鬱) 更多 | - | 2012-06-28 | ||
(Avanafil 100 mg) | 簾繭繭憲衊糧衊壓築鬱(膚醖膚網醖糧範積選艱) = 窪窪鏇廠膚衊鑰糧選餘 鹹醖簾鏇蓋艱簾積網選 (襯積衊廠壓願觸廠顧遞, 築鹹憲襯壓鹽繭艱糧衊 ~ 糧簾襯餘衊餘淵鏇鑰築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用